Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [28] - Full year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [32] - Gross profit for Q4 was $14.7 million, up 21% from $12.1 million in the prior year [28] - Adjusted gross margin for the full year 2025 was 74.2%, an increase of 140 basis points from 72.8% in 2024 [34] - Annualized revenue churn was less than 1% for 2025, with net dollar retention increasing to 115% [33] Business Line Data and Key Metrics Changes - Clinical revenue excluding biopharma grew 31% year-over-year in Q4 2025 [14] - Hemonc volumes grew 27% year-over-year in Q4, indicating strong performance in hemato-oncology testing [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [17] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4, with clinical revenue up 35% year-over-year [15] - North America saw analysis volumes grow 45% year-over-year in Q4 [15] - Asia Pacific revenue grew 44% in Q4, driven by India and Australia [16] - Latin America experienced a recovery with 49% revenue growth in Q4, particularly in Mexico and Brazil [16] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives to modernize its platform [8] - SOPHiA DDM Digital Twins were launched to create AI-driven virtual representations of patients, enhancing treatment decision-making [11] - The company aims to leverage partnerships, such as with MD Anderson, to co-develop new tests and applications [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [42] - The company expects full year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [38] - Adjusted EBITDA loss is projected to be between $29 million and $32 million for 2026, an improvement from 2025 [39] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [7] - The platform's scalability has improved significantly, allowing for faster and more cost-efficient genomic analysis [9] Q&A Session Summary Question: Contributions from key growth drivers for 2026 - Management highlighted strong performance in Q4 with 31% revenue growth and emphasized the ramping of MSK-ACCESS as a key driver for growth [46][47] Question: Net dollar retention and cross-selling strength - Management noted that the re-acceleration in net dollar retention to 115% reflects the platform's stickiness and the ability to expand within accounts [51][52] Question: Potential annual contribution from new pharma contracts - Management indicated that while the pharma business takes time to ramp, they expect a positive contribution in 2026, with ongoing strategic steps to enhance growth [58][60] Question: Expansion potential with new health systems - Management expressed optimism about the potential for significant growth with the two large health systems, indicating opportunities for expansion beyond initial applications [62][65] Question: Volume price mix for 2026 guidance - Management expects ASPs to increase due to higher-priced tests being sold, while also anticipating volume growth in regions with lower ASPs [70][71] Question: New CEO's approach and potential changes - The new CEO emphasized a focus on scaling the business and unlocking the full value of the platform while maintaining a disciplined investment strategy [73][75]

Core Viewpoint - 23andMe Holding Co. intends to file a Form 25 Notification of Delisting with the SEC, which will remove its securities from Nasdaq listing and registration [1][2] Group 1: Company Actions - The company announced its intention to file a Form 25 on or about June 6, 2025, to facilitate its deregistration with the SEC [1] - 23andMe previously initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri on March 23, 2025 [2] Group 2: Stock and Trading Information - Nasdaq suspended trading of 23andMe's Class A common stock on March 31, 2025, and notified the company about the filing of Form 25 [1] - Once the delisting becomes effective, the company plans to file a Form 15 to deregister with the SEC [2]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the assets of 23andMe Holding Co. for $256 million, aiming to enhance its leadership in genetics-guided research and drug development, pending bankruptcy court and regulatory approvals [1][2][3] Group 1: Acquisition Details - The planned acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and Biobank assets, with the transaction expected to close in Q3 2025 [1] - Regeneron will operate 23andMe as a wholly owned subsidiary, continuing its consumer genomics services while excluding the Lemonaid Health business from the purchase [3][4] Group 2: Commitment to Data Privacy - Regeneron emphasizes its commitment to the privacy and ethical use of 23andMe's customer data, planning to work with an independent Customer Privacy Ombudsman to ensure compliance with privacy policies and laws [2][3] - The company has a proven track record in large-scale data management, having linked deidentified DNA sequences from nearly three million participants to electronic health records [2][3] Group 3: Strategic Vision - Regeneron aims to leverage its expertise in genetic research to support 23andMe's mission of helping individuals understand their DNA and improve personal health [2][3] - The acquisition aligns with Regeneron's broader strategy to utilize genetics research for advancing medical treatments and improving societal health outcomes [2][3][4]